UK Government funds facility to test vaccines against COVID-19 variants
The UK Government will invest £29.3 million to test the effectiveness of COVID-19 vaccines against variants in 3,000 blood samples a week.
List view / Grid view
The UK Government will invest £29.3 million to test the effectiveness of COVID-19 vaccines against variants in 3,000 blood samples a week.
Researchers have found that over 80 percent of antibodies target sections of the SARS-CoV-2 Spike protein other than the RBD.
Scientists have developed a 3D lung-on-a-chip model of the distal lung and alveolar structures, enabling the study of COVID-19.
A summit will be held between the UK and CEPI to raise funds for vaccine research and development in a bid to avert future pandemics.
UK Health Secretary Matt Hancock has announced £37 million of funding for genomics and data projects to support the life sciences sector.
Scientists have shown that the SARS-CoV-2 Spike protein can initiate gene expression changes, potentially explaining long COVID symptoms.
A new antibody cocktail made from three mAbs neutralised several SARS-CoV-2 variants in pre-clinical studies.
Four hepatitis C drugs have demonstrated promise as boosters to increase the efficacy of remdesivir against SARS-CoV-2 by as much as tenfold.
A team from the University of Texas at Dallas has shown that a novel buffer solution is effective at stabilising the liposomes and lipid nanoparticles in certain COVID-19 vaccines.
Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
Biliverdin attaches to a region of the SARS-CoV-2 Spike protein, stabilising it so that it is not able to expose its structure to antibodies, a new study has shown.
Using newly developed assays, researchers have characterised the antibody response of individuals infected with SARS-CoV-2.
A new COVID-19 vaccine could provide protection from severe infection from a range of coronaviruses, studies in pigs have shown.
The drug MK-4482 decreased viral levels in the lungs of hamsters treated for SARS-CoV-2 infection, researchers have shown.